Morgan Stanley raised the firm’s price target on BioNTech to $112 from $111 and keeps an Equal Weight rating on the shares. In offering a 2024 outlook for North American Biopharma, the firm says it expects four themes – diabesity, product cycles, policy and rates – to be in focus next year. At the stock level, the firm expects “another year of dispersion” and generally recommends investors continue to focus on companies that can deliver growth in the second half of the decade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX:
- BioNTech to Inaugurate First African Site on December 18, 2023
- BioNTech downgraded to Underweight from Neutral at JPMorgan
- Singapore says Nuvaxovid COVID vaccine won’t be available under NVP as of Jan. 1
- BioNTech price target lowered to $110 from $153 at UBS
- Moderna tells Reuters will appeal European Patent Office decision
